We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

CytoGenix Receives First Order for synDNA™

CytoGenix Receives First Order for synDNA™

CytoGenix Receives First Order for synDNA™

CytoGenix Receives First Order for synDNA™

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CytoGenix Receives First Order for synDNA™ "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CytoGenix, Inc. has announced that it has received its first purchase order for synDNA™ synthetic DNA. The order was placed by Aldevron.

CytoGenix and Aldevron have joined forces to meet the special needs of the market for multi-gram quantities of highly pure DNA.

"The CytoGenix synDNA™ technology allows us to offer a broader range of solutions to gene therapy and DNA vaccine researchers," said Dr. Michael Chambers, President and CEO of Aldevron.

"One of our goals is to help expand the field of DNA-based pharmaceuticals. We welcome the relationship with CytoGenix and look forward to working together to expand the market for high quality DNA."

Dr. Malcolm Skolnick, President and CEO commented, "This is a major milestone for CytoGenix. While our primary goal is to develop our own products, we are pleased to service the growing need for high purity cost-effective DNA."

"We are very excited about our relationship with Aldevron and the opportunity to supply their needs for synDNA™."